Short answer
Oric Pharmaceuticals, Inc. (ORIC) filed its Q1 2026 10-Q quarterly report on May 4, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$36M
- −19.1% YoY
- EPS (diluted)
- −$0.34
- +19.0% YoY
Source: XBRL data from the Oric Pharmaceuticals, Inc. (ORIC) Q1 2026 10-Q on SEC EDGAR. USD.
Oric Pharmaceuticals, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product candidates commercially approved
- Net loss $35.8M vs $30.0M YoY; operating loss $39.6M vs $32.7M
- Rinzimetostat R&D costs $12.1M, up $7.3M; enozertinib costs $6.4M, up $0.3M
- Operating cash used $32.4M vs $32.5M; ATM financing generated $59.9M
- Cash resources expected to fund operations into second half of 2028; substantial additional funding required
Risk Factors
- Financing runway risk: $419.7 million cash, equivalents and investments expected to fund operations into second half of 2028
- Clinical-stage concentration risk: success substantially dependent on rinzimetostat and enozertinib
- Regulatory approval risk: FDA Project Optimus may alter oncology dose-selection requirements
- Loss risk: $35.8 million quarterly net loss and $728.0 million accumulated deficit
- Banking access risk: uninsured or excess-FDIC-limit balances could become inaccessible during bank insolvency
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Oric Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.